>

Isaac Kohlberg - CLAL BIOTECHNOLOGY Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>CLA</div>
  Director
Mr. Isaac T. Kohlberg was appointed Director at Clal Biotechnology Industries Ltd. effective May 7, 2015. His work experience includes the role of Senior Associate Provost, Chief Technology Development Officer at Harvard University from 2005. He holds Directorship in various Companies. He holds a LLB degree from Tel Aviv University and a MBA degree from INSEAD.
Age: 66  Director Since 2015  MBA    
972 3 612 1616  http://www.cbi.co.il

Isaac Kohlberg Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (5.15) % which means that it has lost $5.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.79) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. CLAL BIOTECHNOLOGY has Current Ratio of 3.6 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Company Summary

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.CLAL BIOTECHNOLOGY (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 14 people.

CLAL BIOTECHNOLOGY Leadership Team

Ofer Goldberg, VPView
Sigalia Heifetz, DirectorView
Shmuel Rubinstein, External DirectorView
Tomer Babai, DirectorView
Dafna Gruber, DirectorView
Aharon Schwartz, DirectorView
Gavriel Barabash, DirectorView
Isaac Kohlberg, DirectorView
Nofar Malovani, DirectorView
Assaf Segal, CFOView
Ofer Gonen, Vice PresidentView
Avraham Fischer, Chairman of the BoardView
Yuval Yanai, External DirectorView
Julian Adams, President Chief Scientific OfficerView
Orit Lidor, VP and General CounselView

Stock Performance Indicators

Current Sentiment - CBI

CLAL BIOTECHNOLOGY Investor Sentiment

Most of Macroaxis users are currently bullish on CLAL BIOTECHNOLOGY. What is your opinion about investing in CLAL BIOTECHNOLOGY? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

CLAL BIOTECHNOLOGY Pair Correlation

Equities Pair Trading Analysis

Continue to Trending Equities. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.